Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies achieve objective response rates of 40%-50%, while immunotherapy has not been established. Researchers from the University Hospital Tübingen have presented preclinical data regarding CC-3, a CD276xCD3 bispecific antibody with favorable preclinical safety and efficacy data that is currently being evaluated in phase I clinical trials for c